文献速递重症综合管理与镇静镇痛复苏、休克与脓毒症

年龄对创伤与外科ICU脓毒症/脓毒性休克患者固有免疫反应及结局的影响

The impact of age on the innate immune response and outcomes after severe sepsis/septic shock in trauma and surgical intensive care unit patients.
PubMed 文献 · J Trauma Acute Care Surg · 2018-01-01
一句话结论单中心前瞻观察显示,≥55岁外科/创伤脓毒症患者早期生理紊乱更重、多器官衰竭与6个月病死率更高,生物标志物提示持续免疫抑制与分解代谢。

本研究为单中心前瞻性观察队列,纳入外科ICU严重脓毒症或脓毒性休克患者173例(严重脓毒症93例,53.8%;脓毒性休克80例,46.2%),平均年龄60.9(±14.5)岁,腹腔感染最常见(81例,46.8%)。按年龄分为年轻组(<55岁)与老年组(≥55岁)。老年组合并症负担更高,早期生理紊乱更重(APACHE II中位数23 vs 18,p=0.002),多器官衰竭发生率更高(64.3% vs 40.4%,p=0.006),住院病死率更高(15.9% vs 2.1%,p=0.016),6个月病死率更高(31% vs 9%,p=0.003)。老年患者生物标志物轨迹至脓毒症后28天提示持续免疫抑制(绝对淋巴细胞计数、可溶性程序性死亡配体-1)与分解代谢(尿3MH-Cr比值、胰岛素样生长因子、IGF1BP3、白蛋白)。

要点

  • ≥55岁外科/创伤脓毒症患者多器官衰竭发生率64.3% vs 年轻组40.4%(p=0.006),住院病死率15.9% vs 2.1%(p=0.016)。
  • ≥55岁组6个月病死率31% vs 年轻组9%(p=0.003),早期病情更重(APACHE II中位数23 vs 18,p=0.002)。
  • 老年组合并症负担更高,但其他基线特征与年轻组相似。
  • 老年患者脓毒症后28天内绝对淋巴细胞计数与可溶性程序性死亡配体-1轨迹提示持续免疫抑制,尿3MH-Cr比值、胰岛素样生长因子、IGF1BP3、白蛋白轨迹提示分解代谢。
  • 作者认为高龄可能需要新的治疗策略以促进多系统器官恢复并改善脓毒症后生存。

适用人群与场景

  • 单中心外科ICU的严重脓毒症或脓毒性休克患者,共173例(严重脓毒症93例,53.8%;脓毒性休克80例,46.2%),平均年龄60.9(±14.5)岁。
  • 感染来源以腹腔感染最常见(81例,46.8%),其次为坏死性软组织感染(33例,19.1%)和肺炎(30例,17.3%)。
  • 按年龄分为年轻组(<55岁)与老年组(≥55岁)。

诊断标准与关键阈值

  • 年龄分组界值:<55岁为年轻组,≥55岁为老年组(基于敏感性分析确定)。

研究设计与关键结果

  • 研究类型:单中心、前瞻性观察性队列研究;样本量173例;人群为外科ICU严重脓毒症/脓毒性休克患者。
  • 主要终点结果:老年组(≥55岁)早期生理紊乱更重,APACHE II中位数23 vs 年轻组18(p=0.002)。
  • 老年组多器官衰竭发生率64.3% vs 年轻组40.4%(p=0.006)。
  • 老年组住院病死率15.9% vs 年轻组2.1%(p=0.016)。
  • 老年组6个月病死率31% vs 年轻组9%(p=0.003)。
  • 生物标志物:老年脓毒症患者至脓毒症后28天的绝对淋巴细胞计数、可溶性程序性死亡配体-1轨迹提示持续免疫抑制;尿3MH-Cr比值、胰岛素样生长因子、IGF1BP3、白蛋白轨迹提示分解代谢。

证据类型、等级与局限

  • 证据类型:单中心、前瞻性观察性队列研究;证据等级:预后研究,level II。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对≥55岁外科/创伤脓毒症患者,应关注其更高的多器官衰竭风险(64.3% vs 40.4%)和住院病死率(15.9% vs 2.1%),以及6个月病死率(31% vs 9%)。
  • 作者认为高龄可能需要新的治疗策略以促进多系统器官恢复并改善脓毒症后生存;原文未据此给出具体推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Advancing age is a strong risk factor for adverse outcomes across multiple disease processes. However, septic surgical and trauma patients are unique in that they incur two or more inflammatory insults. The effects of advanced age on sepsis pathophysiology and outcomes remain unclear.

METHODS: We performed a single-center, prospective observational cohort study of surgical intensive care unit patients with severe sepsis/septic shock. Peripheral blood was collected for genomic, cytokine, and biomarker analysis at 0.5 day, 1 day, 4 days, 7 days, 14 days, 21 days, and 28 days after sepsis onset. Based on sensitivity analysis, cohorts were defined as "young" (<55 years) and "aged" (≥55 years). We compared age-defined cohorts to determine differences in patient characteristics, biomarker profiles, and clinical outcomes.

RESULTS: The cohort included 173 patients with severe sepsis (n = 93; 53.8%) or septic shock (n = 80; 46.2%), with a mean age of 60.9 (±14.5) years. Intra-abdominal sepsis was the leading source (n = 81; 46.8%), followed by necrotizing soft tissue infection (n = 33, 19.1%) and pneumonia (n = 30; 17.3%). Aged patients had a higher comorbidity burden, but were otherwise similar to the young cohort. The aged cohort had a higher severity of early physiologic derangement (median APACHE II, 23 vs. 18; p = 0.002), greater incidence of multiple organ failure (64.3% vs. 40.4%, p = 0.006), and hospital mortality (15.9% vs. 2.1%; p = 0.016). Six-month mortality was significantly higher in the aged cohort as compared with young cohort (31% vs. 9%; p = 0.003). Aged septic patients biomarker trajectories suggestive of persistent immunosuppression (absolute lymphocyte count, soluble programed death ligand-1) and catabolism (Urine 3MH-Cr ratio, insulin growth factor, IGF1BP3, albumin) out to 28 days after sepsis.

CONCLUSION: Aged, critically ill surgical patients have greater organ dysfunction and incidence of adverse clinical outcomes after sepsis. Biomarker profiles suggest an immunophenotype of persistent immunosuppression and catabolism. Advanced age may necessitate novel therapeutic strategies to promote multisystem organ recovery and improve survival after sepsis.

LEVEL OF EVIDENCE: Prognostic, level II.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Brakenridge SC, Efron PA, Stortz JA, et al. The impact of age on the innate immune response and outcomes after severe sepsis/septic shock in trauma and surgical intensive care unit patients. J Trauma Acute Care Surg. 2018. PMID: 29613958. doi:10.1097/TA.0000000000001921

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。